纳米孔
肺结核
分析物
结核分枝杆菌
抗原
生物传感器
纳米孔测序
临床诊断
纳米技术
金标准(测试)
结核分枝杆菌复合物
疾病
医学
病毒学
免疫学
生物
材料科学
化学
色谱法
内科学
病理
重症监护医学
基因组
生物化学
基因
作者
Xiaoqin Wang,Xiaojun Wei,Marieke M. van der Zalm,Zehui Zhang,Nandhini Subramanian,Anne‐Marie Demers,Elisabetta Walters,Anneke C. Hesseling,Chang Liu
出处
期刊:ACS Nano
[American Chemical Society]
日期:2023-08-29
卷期号:17 (21): 21093-21104
被引量:11
标识
DOI:10.1021/acsnano.3c04420
摘要
Nanopore sensing of proteomic biomarkers lacks accuracy due to the ultralow abundance of targets, a wide variety of interferents in clinical samples, and the mismatch between pore and analyte sizes. By converting antigens to DNA probes via click chemistry and quantifying their characteristic signals, we show a nanopore assay with several amplification mechanisms to achieve an attomolar level limit of detection that enables quantitation of the circulating Mycobacterium tuberculosis (Mtb) antigen ESAT-6/CFP-10 complex in human serum. The assay's nonsputum-based feature and low-volume sample requirements make it particularly well-suited for detecting pediatric tuberculosis (TB) disease, where establishing an accurate diagnosis is greatly complicated by the paucibacillary nature of respiratory secretions, nonspecific symptoms, and challenges with sample collection. In the clinical assessment, the assay was applied to analyze ESAT-6/CFP-10 levels in serum samples collected during baseline investigation for TB in 75 children, aged 0-12 years, enrolled in a diagnostic study conducted in Cape Town, South Africa. This nanopore assay showed superior sensitivity in children with confirmed TB (94.4%) compared to clinical "gold standard" diagnostic technologies (Xpert MTB/RIF 44.4% and Mtb culture 72.2%) and filled the diagnostic gap for children with unconfirmed TB, where these traditional technologies fell short. We envision that, in combination with automated sample processing and portable nanopore devices, this methodology will offer a powerful tool to support the diagnosis of pulmonary TB in children.
科研通智能强力驱动
Strongly Powered by AbleSci AI